(Q33640488)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24673698%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

Inhaled antibiotics for lower airway infections (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24673698%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24673698%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Bradley S Quon

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24673698%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Bonnie W Ramsey

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24673698%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

publication date

1 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24673698%20AND%20SRC:MED&resulttype=core&format=json

Proceedings of the American Thoracic Society

12 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24673698%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24673698%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24673698%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

425-434

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24673698%20AND%20SRC:MED&resulttype=core&format=json

Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease

12 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Is universal antifungal prophylaxis mandatory in lung transplant patients?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Treatment of lung infection in patients with cystic fibrosis: current and future strategies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Inhaled antibiotics for long-term therapy in cystic fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Development of an Inhaled Dry-Powder Formulation of Tobramycin Using PulmoSphere™ Technology

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Development of the First Inhaled Antibiotic for the Treatment of Cystic Fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Inhaled drug therapy for treatment of tuberculosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

An 18‐month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

British Thoracic Society guideline for non-CF bronchiectasis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Aerosolized antibiotics to treat ventilator-associated pneumonia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Tobramycin Nebulizer Solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Fungal infections in lung transplant recipients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Inhalable microparticles containing large payload of anti-tuberculosis drugs

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Early intervention and prevention of lung disease in cystic fibrosis: a European consensus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Efficacy and safety of aerosolized tobramycin in cystic fibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Formulation of aerosolized therapeutics

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Anastomotic infections in lung transplant recipients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Controlled Comparison of Amikacin and Gentamicin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Prevention of gram-negative bacillary pneumonia using polymyxin aerosol as prophylaxis. II. Effect on the incidence of pneumonia in seriously ill patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

21 June 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

Inhaled colistin following lung transplantation in colonised cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

Development of liposomal capreomycin sulfate formulations: effects of formulation variables on peptide encapsulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201311-395FR

Donor-to-host transmission of bacterial and fungal infections in lung transplantation

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028738

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

30 October 2018

1 reference

12 December 2020

Levofloxacin Inhalation Solution (MP-376) in Patients with Cystic Fibrosis with Pseudomonas aeruginosa

1 reference

12 December 2020

Nebulized Ceftazidime and Amikacin in Ventilator-associated Pneumonia Caused byPseudomonas aeruginosa

1 reference

12 December 2020

Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI)

1 reference

12 December 2020

Acute renal failure associated with use of inhaled tobramycin for treatment of chronic airway colonization with Pseudomonas aeruginosa

1 reference

12 December 2020

Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis

1 reference

12 December 2020

Exhaled nitric oxide in cystic fibrosis: relationships with airway and lung vascular impairments

1 reference

12 December 2020

Management of nontuberculous mycobacterial (NTM) lung disease

1 reference

12 December 2020

Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis

1 reference

12 December 2020

Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization

1 reference

12 December 2020

Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis

1 reference

12 December 2020

Allograft colonization and infections with pseudomonas in cystic fibrosis lung transplant recipients

1 reference

12 December 2020

Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents

1 reference

12 December 2020

10.1513/ANNALSATS.201311-395FR

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24673698%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24673698%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

PubMed publication ID

24673698

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24673698%20AND%20SRC:MED&resulttype=core&format=json